Proton is developing a small device designed to be inserted just below the skin to continuously monitor potassium levels and pair with a smartphone app for patient alerts. A clinician dashboard is planned so care teams can view potassium trends and fine-tune therapies, potentially reducing in-clinic potassium testing, time, and costs. The company targets patients with chronic kidney disease and those at risk of heart failure, where potassium imbalances can be life‑threatening. Clinical trials are underway for the product, which Proton says is due to launch in 2025. The founders are CEO Sahan Ranamukhaarachchi (based in Vancouver) and CSO Victor Cadarso (based in Melbourne); the company has a commercial HQ in Canada and an R&D subsidiary in Melbourne, Australia. Proton positions its approach against other emerging potassium-monitoring firms and claims greater scalability, usability, and clinical impact.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2024